ADMA Biologics (ADMA) Shares Jump 28% After-Hours: Here’s Why

ADMA Biologics Inc (NASDAQ: ADMA)shares jumped 28.24% to $13.44 in after-hours trading Wednesday after the company reported third-quarter 2026 results, with revenue rising 5% year-over-year and higher earnings guidance for the full year.

ADMA Biologics is a U.S.-based biopharmaceutical company focused on manufacturing, marketing and developing specialty biologics.

ADMA Reports Third-Quarter Results

Revenue increased 5% year over year to $141.1 million from $134.2 million. GAAP net income rose 37% to $49.9 million, or $0.22 per basic share, compared with $36.4 million, or $0.15 per share, a year earlier.

Adjusted EBITDA, a non-GAAP measure, increased 32% to $77.3 million. Adjusted net income rose 31% to $51.1 million, while adjusted basic earnings per share increased 44% to $0.23. Gross margin expanded to 71% from 56% a year earlier.

ASCENIV revenue climbed 31% to $124.7 million, driven by physician adoption, new patient starts and increased utilization. The plasma-derived antibody therapy treats primary immunodeficiency, and its FDA-approved use was expanded in 2026 to include children as young as 2. Revenue from BIVIGAM, a drug made from donated human blood plasma, fell to $15.4 million from $23.8 million a year earlier, amid competitive pricing and channel inventory pressures.

ADMA Raises Adjusted Earnings Outlook

The company reiterated its 2026 revenue outlook of at least $530 million while increasing its minimum adjusted net income expectation to $180 million and adjusted EBITDA outlook to $275 million.

ADMA said favorable ASCENIV demand trends continued into the fourth quarter and noted signs of stabilization in underlying BIVIGAM utilization.

The company also reported constructive FDA feedback on its pre-investigational new drug meeting package for SG-001, an investigational pneumococcal hyperimmune globulin candidate. ADMA plans to incorporate the FDA’s recommendations into its clinical protocol and advance preparations for an investigational new drug submission.

Trading Metrics, Technical Analysis

ADMA Biologics has a market capitalization of approximately $2.35 billion.

Over the past year, the stock has traded between a 52-week high of $20.46 and a 52-week low of $7.21.

Benzinga’s Edge Stock Rankings indicate positive price trends in the short and medium term, but a negative trend in the long term.

Price Action: ADMA Biologics shares fell 5.67% to close at $10.48 during Wednesday’s regular trading session.

Photo: Zakharchuk / Shutterstock